| Bioactivity | Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1)[1]. | ||||||||||||
| Name | Linaprazan glurate | ||||||||||||
| CAS | 1228559-81-6 | ||||||||||||
| Formula | C26H32N4O5 | ||||||||||||
| Molar Mass | 480.56 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Mikael Dahlström, et al. Imidazopyridine derivatives which inhibit the secretion of gastric acid. Patent WO2010063876A1. |
Linaprazan glurate
CAS: 1228559-81-6 F: C26H32N4O5 W: 480.56
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits s
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.